Fulcrum Therapeutics, Inc. Stock Research

Market Summary

USD12.87+0.30

Market Closed

2.39%

FULC Alerts

1 major insider buys and 1 major insider sales recently.

FULC Stock Price

FULC RSI Chart

FULC Valuation

Market Cap

669.9M

Price/Earnings (Trailing)

-6.25

Price/Sales (Trailing)

62.52

Price/Free Cashflow

-6.59

FULC Price/Sales (Trailing)

FULC Profitability

Return on Equity

-48.43%

Return on Assets

-43.27%

Free Cashflow Yield

-15.16%

FULC Fundamentals

FULC Revenue

Revenue (TTM)

10.7M

Revenue Y/Y

-76.03%

Revenue Q/Q

-37.14%

FULC Earnings

Earnings (TTM)

-107.2M

Earnings Y/Y

-14.59%

Earnings Q/Q

30.33%

Price Action

52 Week Range

3.2124.79

(Low)(High)

Last 7 days

1.9%

Last 30 days

94.7%

Last 90 days

137.0%

Trailing 12 Months

11.7%

FULC Financial Health

Current Ratio

15.49

FULC Investor Care

Shares Dilution (1Y)

28.44%

Diluted EPS (TTM)

-2.56

Peers (Alternatives to Fulcrum Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	442.1B	96.0B	-4.77%	1.21%	23.08	4.6	5.02%	7.14%
LLY	308.1B	29.2B	-6.33%	46.49%	51.07	10.54	5.34%	1.02%
MRK	267.0B	59.0B	-5.13%	34.98%	17.49	4.53	27.84%	112.03%
PFE	245.5B	99.9B	-13.80%	-15.92%	8.25	2.46	45.01%	53.21%
BMY	154.0B	46.7B	0.64%	15.96%	23.07	3.3	2.79%	223.53%
MID-CAP
PRGO	5.0B	4.4B	10.03%	-0.57%	-46.66	1.14	1.80%	57.67%
SUPN	2.2B	659.0M	13.79%	40.18%	57.51	3.29	16.78%	-53.92%
SMALL-CAP
TLRY	1.9B	613.6M	24.42%	-38.51%	-3.79	3.14	37.73%	-7.19%
RETA	1.6B	3.1M	23.90%	79.89%	-5.08	503.44	-77.09%	-12.24%
CGC	1.4B	-	33.79%	-57.23%	-0.46	1.95	-4.11%	-144.36%
ACRS	1.2B	23.5M	12.85%	73.07%	-14.2	49.6	243.57%	-1.04%
CRON	942.1M	112.7M	-	-24.55%	-4.21	8.36	45.53%	40.26%
INVA	885.5M	-	-2.61%	-19.99%	2.65	2.34	10.49%	-16.07%
OCUL	298.8M	49.7M	46.97%	-25.95%	-5.03	6.01	28.95%	32.80%
ENDP	94.1M	2.6B	-43.99%	-88.43%	-0.03	0.04	-13.88%	-4855.92%

Financials for Fulcrum Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-25.9%	10,715,000	14,467,000	16,966,000	19,163,000	18,330,000
Operating Expenses	-0.1%	118,862,000	119,029,000	106,975,000	100,217,000	93,612,000
S&GA Expenses	2.7%	41,269,000	40,190,000	35,777,000	30,516,000	26,678,000
R&D Expenses	-2.2%	77,128,000	78,839,000	71,198,000	69,701,000	66,934,000
Interest Expenses	-	0	-	-	-	-
Net Income	-2.9%	-107,220,000.00	-104,198,000.00	-89,776,000.00	-80,847,000.00	-75,083,000.00
Net Income Margin	-38.9%	-10.01	-7.20	-5.29	-4.22	-
Free Cahsflow	-5.4%	-101,578,000.00	-96,353,000.00	-86,055,000.00	-80,191,000.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	26.9%	248	195	220	235	256
Current Assets	30.7%	228	174	200	226	246
Cash Equivalents	126.5%	91	40	33	35	65
Net PPE	-5.9%	7	8	8	7	8
Liabilities	-23.5%	26	34	31	23	25
Current Liabilities	-33.6%	15	22	18	19	21
Shareholder's Equity	37.7%	221	161	189	212	231
Retained Earnings	-6.5%	-386.20	-362.46	-328.39	-302.47	-278.98
Additional Paid-In Capital	16.1%	608	524	519	514	510
Accumulated Depreciation	6.5%	10	9	9	8	8
Shares Outstanding	26.9%	52	41	41	41	41

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-5.7%	-99.21	-93.90	-84.36	-78.48	-76.45
Share Based Compensation	5.3%	14	13	13	11	9
Cashflow From Investing	161.4%	40	-64.68	-122.42	-129.67	-135.17
Cashflow From Financing	-40.1%	85	142	139	187	192

Risks for FULC

What is the probability of a big loss on FULC?

97.8%

Probability that Fulcrum Therapeutics stock will be more than 20% underwater in next one year

97.8%

Probability that Fulcrum Therapeutics stock will be more than 30% underwater in next one year.

94.6%

Probability that Fulcrum Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FULC drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Fulcrum Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for FULC

Cumulative Returns on FULC

-9.6%

3-Year Cumulative Returns

Which funds bought or sold FULC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-25	Lindbrook Capital, LLC	sold off	-100	-2,000	-	-%
2023-01-24	Bank Julius Baer & Co. Ltd, Zurich	added	1.6	-6,000	62,000	-%
2023-01-24	NATIONAL BANK OF CANADA /FI/	unchanged	-	-657	3,343	-%
2023-01-23	Allspring Global Investments Holdings, LLC	sold off	-100	-74,000	-	-%
2023-01-18	COUNTRY TRUST BANK	unchanged	-	-24,246	219,754	0.01%
2023-01-13	Allworth Financial LP	sold off	-100	-1,000	-	-%
2023-01-10	SOA Wealth Advisors, LLC.	new	-	5,824	5,824	-%
2022-11-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	25.42	192,000	372,000	-%
2022-11-16	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-	-	-%
2022-11-16	BNP PARIBAS ARBITRAGE, SNC	new	-	77,268	77,268	-%

Latest Funds Activity

Are funds buying FULC calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own FULC

No. of Funds

FULC Alerts

1 major insider buys and 1 major insider sales recently.

Fulcrum Therapeutics News

Schedule 13G FIlings of Fulcrum Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 23, 2023	cowen financial products llc	615%	1,367,759	SC 13G/A
Jan 06, 2023	ra capital management, l.p.	18.6%	9,686,628	SC 13G/A
Aug 26, 2022	ra capital management, l.p.	13.45%	7e+06	SC 13G
Jun 22, 2022	point72 asset management, l.p.	4.3%	1,750,000	SC 13G
Mar 10, 2022	adage capital partners gp, l.l.c.	5.29%	2,150,000	SC 13G
Mar 09, 2022	cowen financial products llc	5.16%	2,096,890	SC 13G
Feb 14, 2022	third rock ventures iii, l.p.	9.8%	3,962,202	SC 13G/A
Feb 14, 2022	rtw investments, lp	9.5%	3,866,872	SC 13G/A
Feb 11, 2022	suvretta capital management, llc	5.9%	2,375,571	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A

FULC Fair Value

Recent SEC filings of Fulcrum Therapeutics

View All Filings

Date Filed	Form Type	Document
Jan 24, 2023	4	Insider Trading
Jan 23, 2023	SC 13G/A	Major Ownership Report
Jan 18, 2023	424B5	Prospectus Filed
Jan 18, 2023	8-K	Current Report
Jan 17, 2023	424B5	Prospectus Filed
Jan 17, 2023	8-K	Current Report
Jan 13, 2023	4	Insider Trading
Jan 06, 2023	4	Insider Trading
Jan 06, 2023	SC 13G/A	Major Ownership Report
Jan 04, 2023	8-K	Current Report

Latest Insider Trading transactions for FULC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-20	RA CAPITAL MANAGEMENT, L.P.	bought	25,000,000	13	1,923,080	-
2023-01-13	Gould Robert J	sold	-101,490	15	-6,766	interim president & ceo
2023-01-04	RA CAPITAL MANAGEMENT, L.P.	bought	1,314,810	7.27606	180,703	-
2022-12-27	RA CAPITAL MANAGEMENT, L.P.	bought	24,509.9	5.9941	4,089	-
2022-12-19	RA CAPITAL MANAGEMENT, L.P.	bought	582,814	5.8997	98,787	-
2022-12-16	RA CAPITAL MANAGEMENT, L.P.	bought	7,269,830	5.4195	1,341,420	-
2022-12-15	RA CAPITAL MANAGEMENT, L.P.	bought	1,302,470	5.495	237,029	-
2022-12-14	RA CAPITAL MANAGEMENT, L.P.	bought	4,501,570	5.4591	824,600	-
2022-12-13	Third Rock Ventures III, L.P.	sold	-	-	-2,000,000	-
2022-06-07	Gould Robert J	sold	-577,895	8.0898	-71,435	-

About Fulcrum Therapeutics

Bryan E. Stuart

www.fulcrumtx.com

100

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Income Statement

2022-09-30

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Collaboration revenue	$ 1,183	$ 4,935	$ 5,657	$ 14,105
Operating expenses:
Research and development	15,366	17,077	58,216	50,789
General and administrative	9,707	8,628	31,564	20,811
Restructuring expenses	465	0	465	0
Total operating expenses	25,538	25,705	90,245	71,600
Loss from operations	(24,355)	(20,770)	(84,588)	(57,495)
Other income, net	617	54	852	132
Net loss	$ (23,738)	$ (20,716)	$ (83,736)	$ (57,363)
Net loss per share, basic	$ (0.51)	$ (0.57)	$ (1.97)	$ (1.71)
Net loss per share, diluted	$ (0.51)	$ (0.57)	$ (1.97)	$ (1.71)
Weighted-average common shares outstanding, basic	46,213	36,606	42,603	33,603
Weighted-average common shares outstanding, diluted	46,213	36,606	42,603	33,603
Comprehensive loss:
Net loss	$ (23,738)	$ (20,716)	$ (83,736)	$ (57,363)
Other comprehensive (loss) gain:
Unrealized gain (loss) on marketable securities	147	(78)	(524)	(85)
Total other comprehensive loss	147	(78)	(524)	(85)
Comprehensive loss	$ (23,591)	$ (20,794)	$ (84,260)	$ (57,448)

FULC Balance Sheet

2022-09-30

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 90,938	$ 35,412
Marketable securities	130,851	182,750
Accounts receivable	13	2,500
Unbilled accounts receivable	790	1,137
Prepaid expenses and other current assets	5,135	4,199
Total current assets	227,727	225,998
Property and equipment, net	7,375	7,368
Operating lease right-of-use assets	9,513	0
Restricted cash	1,092	1,092
Other assets	2,098	542
Total assets	247,805	235,000
Current liabilities:
Accounts payable	2,728	4,788
Accrued expenses and other current liabilities	8,039	9,231
Deferred revenue, current portion	1,389	4,711
Operating Lease Liability, current	2,543	0
Deferred lease incentive, current portion	0	469
Total current liabilities	14,699	19,199
Operating lease liability, excluding current portion	11,495	0
Other liabilities, excluding current portion	197
Deferred rent, excluding current portion		1,680
Deferred lease incentive, excluding current portion	0	2,582
Total liabilities	26,391	23,461
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized; 41,008,205 and 40,636,398 shares issued as of June 30, 2022 and December 31, 2021, respectively; 41,008,205 and 40,626,224 shares outstanding as of June 30, 2022 and December 31, 2021, respectively	52	41
Treasury stock, at cost; no shares	0	0
Additional paid-in capital	608,486	514,362
Accumulated other comprehensive loss	(921)	(397)
Accumulated deficit	(386,203)	(302,467)
Total stockholders’ equity	221,414	211,539
Total liabilities and stockholders’ equity	$ 247,805	$ 235,000